Browse editorial coverage, explainers, and reviews related to MOTS-c.
3 articles
MOTS-c has finally entered human efficacy testing in the exact metabolic scenario that drove years of interest. A recruiting Phase 2a trial means the peptide's metabolism story is now being proven in real people, not just lab research.
LL-37 now has a sharper immune story: a 2025 paper links it to cGAMP transport, STING signaling, and interferon-based antiviral activity. That makes the peptide easier to understand in longevity circles, even if the practical evidence is still early.
MOTS-c dosage is still more routine question than fixed standard. Here's how longevity-focused dosing conversations usually work, what the current evidence actually supports, and why timing, cycle length, and injection setup matter more than a single number.